Jamal El Bakali

505 citations

24 papers · 405 indexed · h-index 12

Co-authors: Benoît Déprez Rebecca Deprez‐Poulain Xiaoan Wen Philippe Chavatte Régis Millet Pierre Desreumaux Nicolas Renault Madjid Djouina
Topics: Cannabis and Cannabinoid Research (6 papers)Pharmacological Receptor Mechanisms and Effects (6 papers)Tuberculosis Research and Epidemiology (4 papers)
Cited by: Pharmacology Organic Chemistry Biological Psychiatry
Journals: Angewandte Chemie International Edition International Journal of Molecular Sciences Journal of Medicinal Chemistry
Partner nations: France Belgium United Kingdom

In The Last Decade

Jamal El Bakali

24 papers receiving 397 citations

Peers

Countries citing papers authored by Jamal El Bakali

Since Specialization

Citations

This map shows the geographic impact of Jamal El Bakali's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jamal El Bakali with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jamal El Bakali more than expected).

Fields of papers citing papers by Jamal El Bakali

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jamal El Bakali. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jamal El Bakali. The network helps show where Jamal El Bakali may publish in the future.

Co-authorship network of co-authors of Jamal El Bakali

This figure shows the co-authorship network connecting the top 25 collaborators of Jamal El Bakali. A scholar is included among the top collaborators of Jamal El Bakali based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jamal El Bakali. Jamal El Bakali is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode 2025 ·Angewandte Chemie International Edition ·(unknown),Séverine Ravez,Didier Vertommen,Nicolas Renault,Nicolas Papadopoulos,(unknown),(unknown),Karine Porte,(unknown),Nathalie Hennuyer,Gaëtan Herinckx,(unknown),Aurélie Jonneaux,Jean‐Christophe Devedjian,David Devos,Bart Staels,Patricia Melnyk,Stefan N. Constantinescu,Raphaël Frédérick,Jamal El Bakali	4
2	LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode 2025 ·Angewandte Chemie ·(unknown),Séverine Ravez,Didier Vertommen,Nicolas Renault,Nicolas Papadopoulos,(unknown),(unknown),Karine Porte,(unknown),Nathalie Hennuyer,Gaëtan Herinckx,(unknown),Aurélie Jonneaux,Jean‐Christophe Devedjian,David Devos,Bart Staels,Patricia Melnyk,Stefan N. Constantinescu,Raphaël Frédérick,Jamal El Bakali	2
3	Discovery of Potent Acyl-CoA Synthetase Long-Chain Family Member 4 (ACSL4) Inhibitors with Antiferroptotic Properties 2025 ·Journal of Medicinal Chemistry ·(unknown),(unknown),(unknown),(unknown),Nicolas Renault,Aurélie Jonneaux,(unknown),(unknown),Jean‐Christophe Devedjian,Patricia Melnyk,Saı̈d Yous,David Devos,Raphaël Frédérick,Séverine Ravez,Jamal El Bakali	1
4	A Polyaminobiaryl-Based β-secretase Modulator Alleviates Cognitive Impairments, Amyloid Load, Astrogliosis, and Neuroinflammation in APPSwe/PSEN1ΔE9 Mice Model of Amyloid Pathology 2023 ·International Journal of Molecular Sciences ·(unknown),(unknown),(unknown),Luc Buée,Jamal El Bakali,Patricia Melnyk,Nicolas Sergeant	5
5	Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference** 2023 ·Angewandte Chemie International Edition ·Jamal El Bakali,M. Błaszczyk,Joanna C. Evans,(unknown),William J. McCarthy,(unknown),M.V.B. Dias,Eachan O. Johnson,Anthony G. Coyne,Valerie Mizrahi,Tom L. Blundell,Chris Abell,Christina Spry	8
6	Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference** 2023 ·Angewandte Chemie ·Jamal El Bakali,M. Błaszczyk,Joanna C. Evans,(unknown),William J. McCarthy,(unknown),M.V.B. Dias,Eachan O. Johnson,Anthony G. Coyne,Valerie Mizrahi,Tom L. Blundell,Chris Abell,Christina Spry	1
7	Repositioning of FDA-Approved antifungal agents to interrogate Acyl-CoA synthetase long chain family member 4 (ACSL4) in ferroptosis 2022 ·Biochemical Pharmacology ·(unknown),Séverine Ravez,(unknown),(unknown),Karine Porte,Jean-Christophe Devedjian,Patricia Melnyk,David Devos,Raphaël Frédérick,Jamal El Bakali	12
8	Structural Characterization of Mycobacterium abscessus Phosphopantetheine Adenylyl Transferase Ligand Interactions: Implications for Fragment-Based Drug Design 2022 ·Frontiers in Molecular Biosciences ·S.E. Thomas,William J. McCarthy,Jamal El Bakali,Karen Brown,So Yeon Kim,M. Błaszczyk,V. Mendes,Chris Abell,R. Andrés Floto,Anthony G. Coyne,Tom L. Blundell	8
9	A ß-Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration 2021 ·Frontiers in Pharmacology ·(unknown),Sabiha Eddarkaoui,(unknown),(unknown),Jamal El Bakali,(unknown),(unknown),(unknown),David Blum,Luc Buée,Patricia Melnyk,Nicolas Sergeant	1
10	Using a Fragment-Based Approach to Identify Alternative Chemical Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis 2020 ·ACS Infectious Diseases ·(unknown),(unknown),Gerardo Andrés Libreros-Zúñiga,(unknown),Petros A. Tyrakis,(unknown),(unknown),Jamal El Bakali,Silvana A. Rocco,Maurício L. Sforça,Roberto Parise‐Filho,Anthony G. Coyne,Tom L. Blundell,Chris Abell,M.V.B. Dias	14
11	A phenotypic approach to the discovery of compounds that promote non-amyloidogenic processing of the amyloid precursor protein: Toward a new profile of indirect β-secretase inhibitors 2018 ·European Journal of Medicinal Chemistry ·(unknown),(unknown),(unknown),Pascal Carato,Nicolas Renault,(unknown),Sabiha Eddarkaoui,Catherine Baud,(unknown),Luc Buée,Jamal El Bakali,Valérie Vingtdeux,Nicolas Sergeant,Patricia Melnyk	8
12	Antagonists of the adenosine A 2A receptor based on a 2-arylbenzoxazole scaffold: Investigation of the C5- and C7-positions to enhance affinity 2017 ·European Journal of Medicinal Chemistry ·(unknown),(unknown),Nicolas Renault,Jamal El Bakali,Christophe Furman,Patricia Melnyk,Saı̈d Yous	7
13	Inhibition of Aggrecanases as a Therapeutic Strategy in Osteoarthritis 2014 ·Future Medicinal Chemistry ·Jamal El Bakali,Hélène Gras-Masse,(unknown),Benoît Déprez,Julie Dumont,Florence Leroux,Rebecca Deprez‐Poulain	15
14	Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group 2013 ·European Journal of Medicinal Chemistry ·(unknown),Jamal El Bakali,Julie Dumont,Damien Bosc,(unknown),(unknown),(unknown),Bruno O. Villoutreix,Hideaki Nagase,Olivier Spérandio,Florence Leroux,Benoît Déprez,Rebecca Deprez‐Poulain	16
15	3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis 2013 ·Bioorganic & Medicinal Chemistry ·(unknown),(unknown),Mathilde Body–Malapel,(unknown),Amélie Lemoine,Roxane Mansouri,Madjid Djouina,Nicolas Renault,Jamal El Bakali,Pierre Desreumaux,Giulio G. Muccioli,Didier M. Lambert,Philippe Chavatte,Benoı̂t Rigo,Natascha Leleu‐Chavain,Régis Millet	34
16	Virtual Screening of CB₂ Receptor Agonists from Bayesian Network and High‐Throughput Docking: Structural Insights into Agonist‐Modulated GPCR Features 2012 ·Chemical Biology & Drug Design ·Nicolas Renault,(unknown),Amaury Farce,Jamal El Bakali,Roxane Mansouri,Philippe Gervois,Régis Millet,Pierre Desreumaux,Christophe Furman,Philippe Chavatte	19
17	Efficient propylphosphonic anhydride (®T3P) mediated synthesis of benzothiazoles, benzoxazoles and benzimidazoles 2012 ·Tetrahedron Letters ·Xiaoan Wen,Jamal El Bakali,Rebecca Deprez‐Poulain,Benoît Déprez	107
18	Novel selective inhibitors of neutral endopeptidase: discovery by screening and hit-to-lead optimisation 2012 ·MedChemComm ·Jamal El Bakali,(unknown),Julie Dumont,(unknown),(unknown),(unknown),(unknown),Florence Leroux,Benoît Déprez,Rebecca Deprez‐Poulain	2
19	New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis 2011 ·Bioorganic & Medicinal Chemistry ·(unknown),Giulio G. Muccioli,Mathilde Body–Malapel,Jamal El Bakali,Madjid Djouina,Nicolas Renault,Philippe Chavatte,Pierre Desreumaux,Didier Lambert,Régis Millet	38
20	2,6-Diphenylthiazolo[3,2-b][1,2,4]triazoles as telomeric G-quadruplex stabilizers 2009 ·Bioorganic & Medicinal Chemistry Letters ·Jamal El Bakali,Frédérique Klupsch,Aurore Guédin,(unknown),Gaëlle Fontaine,Amaury Farce,Pascal Roussel,Raymond Houssin,Jean‐Luc Bernier,Philippe Chavatte,Jean‐Louis Mergny,Jean‐François Riou,Jean‐Pierre Hénichart	22

About Jamal El Bakali

Jamal El Bakali is a scholar working on Pharmacology, Neurology and Physiology, having authored 24 papers that have together received 405 indexed citations. Recurring topics across this work include Cannabis and Cannabinoid Research (6 papers), Pharmacological Receptor Mechanisms and Effects (6 papers) and Tuberculosis Research and Epidemiology (4 papers). The work is most often cited by research in Pharmacology (111 citations), Organic Chemistry (183 citations) and Biological Psychiatry (10 citations). Jamal El Bakali has collaborated with scholars based in France, Belgium and United Kingdom. Frequent co-authors include Benoît Déprez, Rebecca Deprez‐Poulain, Xiaoan Wen, Philippe Chavatte, Régis Millet, Pierre Desreumaux, Nicolas Renault, Madjid Djouina, Giulio G. Muccioli and Mathilde Body–Malapel. Their work appears in journals such as Angewandte Chemie International Edition, International Journal of Molecular Sciences and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact